株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の掻痒治療薬市場:2019~2023年

Global Pruritus Therapeutic Market 2019-2023

発行 TechNavio (Infiniti Research Ltd.) 商品コード 538564
出版日 ページ情報 英文 81 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
世界の掻痒治療薬市場:2019~2023年 Global Pruritus Therapeutic Market 2019-2023
出版日: 2019年07月12日発行予定 ページ情報: 英文 81 Pages
概要

世界の掻痒治療薬市場は2017~2021年にかけCAGR4.95%で拡大するとみられています。様々な全身性疾患が掻痒の原因となり、生化学的要因の変化やバランスの乱れを引き起こし、掻痒につながっています。

当レポートでは、世界の掻痒治療薬市場について調査し、市場の動向と課題、疾患別、投与ルート別、地域別動向、および市場に参入する主要ベンダーのプロファイルなどをまとめています。

第1章 エグゼクティブサマリー

第2章 当レポートの範囲

第3章 調査方法

第4章 イントロダクション

第5章 市場概要

第6章 パイプライン環境

第7章 疾患別市場セグメンテーション

  • 腎性掻痒
  • 胆汁鬱滞性掻痒
  • 血液学的掻痒
  • 内分泌性掻痒
  • 腫瘍性掻痒

第8章 投与ルート別市場セグメンテーション

第9章 地域別セグメンテーション

  • 南北アメリカ
  • 欧州・中東・アフリカ
  • アジア太平洋地域

第10章 意思決定の枠組み

第11章 促進因子と課題

第12章 市場動向

  • 新規T細胞サブセットの同定
  • 製品開発のための新たな技術の組み込み
  • 無機的成長戦略

第13章 ベンダー環境

  • 競合シナリオ

第14章 主要ベンダー分析

  • Allergan
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • その他の注目ベンダー

第15章 付録

図表

図表
  • Exhibit 01: Types of pruritus based on causative disease
  • Exhibit 02: Chemical substances that trigger pruritus
  • Exhibit 03: Major diseases that cause pruritus
  • Exhibit 04: Major drug classes that induce pruritus
  • Exhibit 05: Global pruritus therapeutic market drivers
  • Exhibit 06: Global pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 07: Opportunity analysis in global pruritus therapeutic market
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Pipeline molecules based on vendors
  • Exhibit 10: Key clinical trials
  • Exhibit 11: Segmentation of global pruritus therapeutic market by disease type 2016
  • Exhibit 12: Segmentation of global pruritus therapeutic market share by disease type 2016
  • Exhibit 13: Global renal pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 14: Global cholestatic pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 15: Global hematologic pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 16: Global endocrine pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 17: Global oncological pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 18: Various ROAs applied for pruritic drugs 2016
  • Exhibit 19: Segmentation of global pruritus therapeutic market by geography 2016 and 2021
  • Exhibit 20: Global pruritus therapeutic market revenue by geography 2016-2021 ($ millions)
  • Exhibit 21: Market scenario in Americas
  • Exhibit 22: Pruritus therapeutic market in Americas 2016-2021 ($ millions)
  • Exhibit 23: Market scenario in EMEA
  • Exhibit 24: Pruritus therapeutic market in EMEA 2016-2021 ($ millions)
  • Exhibit 25: Market scenario in APAC
  • Exhibit 26: Pruritus therapeutic market in APAC 2016-2021 ($ millions)
  • Exhibit 27: Prevalence of pruritus in various disease conditions
  • Exhibit 28: Various drugs responsible for inducing pruritus
  • Exhibit 29: Phase III drugs for management of pruritus
  • Exhibit 30: Global sales of Allegra 2008 and 2016 ($ millions)
  • Exhibit 31: Role of newer T-cell subsets in dermatological diseases
  • Exhibit 32: Inorganic growth strategies
  • Exhibit 33: Competitive structure analysis of global pruritus therapeutic market 2016
  • Exhibit 34: Market penetration of various global pruritus therapeutic manufacturers 2016
  • Exhibit 35: Strategic success factors of companies in global pruritus therapeutic market
  • Exhibit 36: Allergan: Key highlights
  • Exhibit 37: Allergan: Strength assessment
  • Exhibit 38: Allergan: Strategy assessment
  • Exhibit 39: Allergan: Opportunity assessment
  • Exhibit 40: GlaxoSmithKline: Key highlights
  • Exhibit 41: GlaxoSmithKline: Strength assessment
  • Exhibit 42: GlaxoSmithKline: Strategy assessment
  • Exhibit 43: GlaxoSmithKline: Opportunity assessment
  • Exhibit 44: Pfizer: Key highlights
  • Exhibit 45: Pfizer: Strength assessment
  • Exhibit 46: Pfizer: Strategy assessment
  • Exhibit 47: Pfizer: Opportunity assessment
  • Exhibit 48: Sanofi: Key highlights
  • Exhibit 49: Sanofi: Strength assessment
  • Exhibit 50: Sanofi: strategy assessment
  • Exhibit 51: Sanofi: opportunity assessment
目次
Product Code: IRTNTR13976

About Global Pruritus Therapeutic

Pruritus is defined as the unpleasant skin sensation that frequently provokes scratching. Various systemic diseases are the major cause of pruritus. The intensity of sensation ranges from mild to severe. Various diseases cause changes/imbalance of biochemical factors, which trigger skin sensation and lead to pruritus. The market is segmented based on these disease conditions, which are responsible for pruritus.

Technavio's analysts forecast the global pruritus therapeutic market to grow at a CAGR of 4.95% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global pruritus therapeutic market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Pruritus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • GlaxoSmithKline
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Abbott
  • Ajanta Pharma
  • Almirall
  • Astellas Pharma
  • Bristol-Myers Squibb
  • CARA Therapeutic
  • Cipla
  • Eisai
  • Eli Lilly
  • Galderma
  • Glenmark
  • Heron Therapeutic
  • IPCA
  • Lupin
  • Merck
  • Novartis
  • Sun Pharma
  • Takeda Pharmaceutical

Market driver

  • Drug-induced pruritus
  • For a full, detailed list, view our report

Market challenge

  • Poor patient adherence due to inadequate information on drug usage
  • For a full, detailed list, view our report

Market trend

  • Incorporation of novel technology for product development
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market overview

  • Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by disease type

  • Renal pruritus
  • Cholestatic pruritus
  • Hematologic pruritus
  • Endocrine pruritus
  • Oncological pruritus

PART 08: Market segmentation by route of administration (ROA)

PART 09: Geographical segmentation

  • Pruritus therapeutic market in Americas
  • Pruritus therapeutic market in EMEA
  • Pruritus therapeutic market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Identification of new T-cell subsets (Th17 and Th22)
  • Incorporation of novel technology for product development
  • Inorganic growth strategies

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Allergan
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations
Back to Top